
Patients with inherited forms of advanced prostate, breast, and ovarian cancers caused by mutations in the BRCA1 and BRCA2 genes experienced tumor shrinkage without major side effects when treated with the investigational drug olaparib (AZD-2281), a recently published phase I study showed.
